278 related articles for article (PubMed ID: 25682436)
21. Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
Hirai T; Yamaga R; Fujita A; Itoh T
J Clin Pharm Ther; 2018 Dec; 43(6):829-835. PubMed ID: 29908131
[TBL] [Abstract][Full Text] [Related]
22. The Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Is Associated with the Recovered Ejection Fraction in Patients with Dilated Cardiomyopathy.
Enzan N; Matsushima S; Ide T; Kaku H; Tohyama T; Funakoshi K; Higo T; Tsutsui H
Int Heart J; 2021 Jul; 62(4):801-810. PubMed ID: 34276005
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis.
Shen JI; Saxena AB; Montez-Rath ME; Leng L; Chang TI; Winkelmayer WC
J Nephrol; 2017 Apr; 30(2):281-288. PubMed ID: 27485007
[TBL] [Abstract][Full Text] [Related]
24. Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF.
Beusekamp JC; Tromp J; van der Wal HH; Anker SD; Cleland JG; Dickstein K; Filippatos G; van der Harst P; Hillege HL; Lang CC; Metra M; Ng LL; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zwinderman AH; Rossignol P; Zannad F; Voors AA; van der Meer P
Eur J Heart Fail; 2018 May; 20(5):923-930. PubMed ID: 29327797
[TBL] [Abstract][Full Text] [Related]
25. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population.
Obeyesekere MN; Chan W; Stub D; Prabhu S; Teo EP; Toogood G; Mariani J; Broughton A; Kistler PM
Pacing Clin Electrophysiol; 2010 Jun; 33(6):696-704. PubMed ID: 20059719
[TBL] [Abstract][Full Text] [Related]
26. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
Kuan YC; Huang KW; Yen DJ; Hu CJ; Lin CL; Kao CH
Int J Cardiol; 2016 Oct; 220():462-6. PubMed ID: 27390970
[TBL] [Abstract][Full Text] [Related]
27. Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin II Receptor Blockers in Acute Coronary Syndrome and Preserved Ventricular Ejection Fraction.
Cespón-Fernández M; Raposeiras-Roubín S; Abu-Assi E; Pousa IM; Queija BC; Paz RJC; Erquicia PD; Rodríguez LMD; Rodríguez EL; Busto MC; Barbeira SF; Romo AÍ
Angiology; 2020 Nov; 71(10):886-893. PubMed ID: 32757765
[TBL] [Abstract][Full Text] [Related]
28. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study.
Shih CJ; Chu H; Ou SM; Chen YT
Int J Cardiol; 2015 Nov; 199():283-9. PubMed ID: 26218587
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials.
Hoang V; Alam M; Addison D; Macedo F; Virani S; Birnbaum Y
Cardiovasc Drugs Ther; 2016 Apr; 30(2):189-98. PubMed ID: 26861251
[TBL] [Abstract][Full Text] [Related]
30. Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Geriatric Ischemic Stroke Patients: Are the Rates Right?
Brooks JM; Chapman CG; Suneja M; Schroeder MC; Fravel MA; Schneider KM; Wilwert J; Li YJ; Chrischilles EA; Brenton DW; Brenton M; Robinson J
J Am Heart Assoc; 2018 May; 7(11):. PubMed ID: 29848495
[TBL] [Abstract][Full Text] [Related]
31. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk.
Potier L; Roussel R; Elbez Y; Marre M; Zeymer U; Reid CM; Ohman M; Eagle KA; Bhatt DL; Steg PG;
Heart; 2017 Sep; 103(17):1339-1346. PubMed ID: 28285267
[TBL] [Abstract][Full Text] [Related]
32. Effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in dialysis patients: a nationwide data survey and propensity analysis.
Wu CK; Yang YH; Juang JJ; Wang YC; Tsai CT; Lai LP; Hwang JJ; Chiang FT; Chen PC; Lin JL; Lin LY
Medicine (Baltimore); 2015 Jan; 94(3):e424. PubMed ID: 25621694
[TBL] [Abstract][Full Text] [Related]
33. CAC score as a possible criterion for administration of angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers: the MultiEthnic Study of Atherosclerosis.
Darabian S; Luo Y; Homat A; Khosraviani K; Wong N; Zeb I; Nasir K; Budoff MJ
Coron Artery Dis; 2015 Dec; 26(8):678-85. PubMed ID: 26398149
[TBL] [Abstract][Full Text] [Related]
34. Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study.
Shen JI; Saxena AB; Vangala S; Dhaliwal SK; Winkelmayer WC
BMC Nephrol; 2017 Jun; 18(1):196. PubMed ID: 28623899
[TBL] [Abstract][Full Text] [Related]
35. Patterns of Use and Clinical Outcomes with Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Heart Failure and Changes in Kidney Function: An Analysis of the Veterans' Health Administrative Database.
Mathew RO; Lo KB; Tipparaju P; Phelps E; Sidhu MS; Bangalore S; Herzog C; Vaduganathan M; Tang WHW; Rangaswami J
Cardiorenal Med; 2021; 11(5-6):226-236. PubMed ID: 34601469
[TBL] [Abstract][Full Text] [Related]
36. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
[TBL] [Abstract][Full Text] [Related]
37. Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome.
Palazzuoli A; Mancone M; De Ferrari GM; Forleo G; Secco GG; Ruocco GM; D'Ascenzo F; Monticone S; Paggi A; Vicenzi M; Palazzo AG; Landolina M; Taravelli E; Tavazzi G; Blasi F; Infusino F; Fedele F; De Rosa FG; Emmett M; Schussler JM; Tecson KM; McCullough PA
J Am Heart Assoc; 2020 Nov; 9(22):e017364. PubMed ID: 33023356
[TBL] [Abstract][Full Text] [Related]
38. Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease.
Huang RS; Cheng YM; Zeng XX; Kim S; Fu P
Chin Med J (Engl); 2016 Mar; 129(5):562-9. PubMed ID: 26904991
[TBL] [Abstract][Full Text] [Related]
39. Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease.
Fröhlich H; Nelges C; Täger T; Schwenger V; Cebola R; Schnorbach J; Goode KM; Kazmi S; Katus HA; Cleland JG; Clark AL; Frankenstein L
Am Heart J; 2016 Aug; 178():28-36. PubMed ID: 27502849
[TBL] [Abstract][Full Text] [Related]
40. Blockade of Renin-Angiotensin-Aldosterone System in Elderly Patients with Heart Failure and Chronic Kidney Disease: Results of a Single-Center, Observational Cohort Study.
Martínez-Milla J; García MC; Urquía MT; Castillo ML; Arbiol AD; Monteagudo ALR; Mariscal MLM; Figuero SB; Franco-Pelaéz JA; Tuñón J
Drugs Aging; 2019 Dec; 36(12):1123-1131. PubMed ID: 31493202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
